Products for Research Use Only

Carmofur (Standard)

CAT: 0804-HY-B0182R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0182R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA) . Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) [1][2][3].
CAS Number
61422-45-5
Product Name Alternative
HCFU (Standard)
UNSPSC
12352005
Target
Ceramidase; FAAH; Glutathione Peroxidase; Nucleoside Antimetabolite/Analog; Reference Standards; SARS-CoV; Virus Protease
Type
Reference Standards
Related Pathways
Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Neuronal Signaling; Others
Field of Research
Cancer; Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/carmofur-standard.html
Smiles
O=C(N(C(N1)=O)C=C(F)C1=O)NCCCCCC
Molecular Formula
C11H16FN3O3
Molecular Weight
257.26
References & Citations
[1]Jin Z, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol. 2020 Jun;27 (6) :529-532.|[2]Realini N, Solorzano C, Pagliuca C, et al. Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity[J]. Scientific reports, 2013, 3 (1) : 1035.|[3]Wu K, et al. A new use for an old drug: carmofur attenuates lipopolysaccharide (LPS) -induced acute lung injury via inhibition of FAAH and NAAA activities[J]. Frontiers in pharmacology, 2019, 10: 818.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards